← Back to Search

EHR-Based Interventions for Breast and Ovarian Cancer Genetic Testing

N/A

Waitlist Available

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Unaffected individuals reporting a family history of breast cancer <50 years

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within one month of receiving referral

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to increase genetic testing and counseling to help save lives through life-saving screenings.

Who is the study for?

This trial is for people with a family history of breast or ovarian cancer, especially if diagnosed before age 50, and those with specific types of these cancers diagnosed over two years ago. It's not open to anyone who has already had genetic counseling or testing.

What is being tested?

The study tests different ways to communicate through electronic health records (EHR) to see which method increases the rate at which people get genetic testing for breast and ovarian cancer predisposition.

What are the potential side effects?

Since this trial involves communication interventions rather than medications, there are no direct physical side effects. However, learning about genetic risks can have emotional or psychological impacts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My family has a history of breast cancer before age 50.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within one month of receiving mpm

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within one month of receiving mpm

This trial's timeline: 3 weeks for screening, Varies for treatment, and within one month of receiving mpm for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Genetic Counseling Appointments Completed Following MPM Delivery

Number of Genetic Counseling Appointments Completed Following Provider Nudge

Secondary study objectives

Open Rate of MPM

Response Rate of Way To Health text

Other study objectives

Number of Signed Referrals

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Sequential CommunicationsExperimental Treatment1 Intervention

This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.

0 / 1Eligibility criteria met